Pharmaceutical CAS 18323 -44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin

Model NO.
D-sung Clindamycin
Shelf Life
2 Years
CAS No.
18323-44-9
Test Method
HPLC
Specific
COA
Boiling Point
134 C
Density
1.1184
MW
424.98
Mf
C18h33cln2o5s
Grade
Pharmaceutical Grade
Color
White
Application
Pharmaceutical
Assay
HPLC 99%
Name
Clindamycin Powder
Appearance
White Powder
Product Name
Clindamycin
Transport Package
Negotiable
Specification
99%
Trademark
D-sung
Origin
Shaanxi Xi′an
Production Capacity
1000kg/Month
Reference Price
$ 49.50 - 58.50
Contact Us

Product Description

Pharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin
Pharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin
Product Description
Pharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder ClindamycinPharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin
Product Details
Pharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin
 
Product nameClindamycin
AppearanceWhite powder
Cas number18323-44-9
MFC18H33ClN2O5S
MW424.98

Clindamycin belongs to the lincomycin class of antibacterial drugs, which is a derivative of lincomycin, and its antibacterial activity is 4 to 8 times stronger than that of lincomycin. This drug acts on the 50s subunit of the ribosome of sensitive bacteria, prevents the elongation of the peptide chain, and inhibits the protein synthesis of bacterial cells to play an anti-Chemicalbook effect. Clinically used for the following infections caused by susceptible strains: otitis media, sinusitis, purulent tonsillitis, pneumonia; skin and soft tissue infections; in the treatment of bone and joint infections, abdominal infections, pelvic infections, empyema, lung abscess, osteomyelitis, Diseases such as sepsis.
Application&Function
Pharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin

1. Respiratory system infections, such as acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, lung abscess, empyema, anaerobic lung disease, bronchiectasis complicated by infection, suppurative otitis media, sinusitis, etc.
2. Urinary system infection, such as acute urethritis, acute pyelonephritis, prostatitis.
3. Female pelvic and genital infections, such as endometritis, non-gonococcal fallopian tube and ovarian abscesses, pelvic cellulitis, and gynecological post-operative infections, are often combined with aminoglycosides.
4. Skin and soft tissue infections, such as acne vulgaris, boils, carbuncles, abscesses, cellulitis, trauma and post-operative infections.
5. Bone and joint infections, such as osteomyelitis (the first choice for the treatment of Staphylococcus aureus osteomyelitis), septic arthritis (very effective for Staphylococcus aureus septic arthritis).
6. Intra-abdominal infection, such as peritonitis, intra-abdominal abscess, bile duct infection, etc.
7. Others, such as endocarditis, sepsis, tonsillitis and oral infection.

Specification
Pharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder ClindamycinPharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin
Pharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin
Pharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder ClindamycinPharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder ClindamycinPharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin
Pharmaceutical CAS 18323-44-9 Clindamycin Raw Material Clindamycin Powder Clindamycin

 

Pharmaceutical Intermediate

PNEUTEC.IT, 2023